IN8bio (INAB)

• Market cap: $14M
• 1 day: 4.04%
• 5 days: -21.29%
• 1 month: -33.58%
• 3 months: -38.37%
• 6 months: -32.83%
• Year to date: -38.37%
• 1 year: -84.98%
• 5 years: -98.27%
• 10 years: -98.27%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

275% more capital invested

Capital invested by funds: $2.06M [Q3] → $7.72M (+$5.66M) [Q4]

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

25.13% more ownership

Funds ownership: 16.3% [Q3] → 41.43% (+25.13%) [Q4]

0% more funds holding

Funds holding: 26 [Q3] → 26 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.20 595% upside
• Avg. target: $3.60 1,985% upside
• High target: $6 3,374% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 45 / 203 met price target	3,374% upside $6	Buy Maintained	14 Mar 2025
Jones Trading Soumit Roy 19% 1-year accuracy 3 / 16 met price target	595% upside $1.20	Buy Upgraded	11 Feb 2025